DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER

被引：59

作者：

SPEIRS, CJ ^{[1
]}

MURRAY, S ^{[1
]}

DAVIES, DS ^{[1
]}

MABADEJE, AFB ^{[1
]}

BOOBIS, AR ^{[1
]}

机构：

[1] ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, DU CANE RD, LONDON W12 0NN, ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1990年 / 29卷 / 01期

基金：

英国惠康基金;

关键词：

D O I：

10.1111/j.1365-2125.1990.tb03608.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non‐cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large. 1990 The British Pharmacological Society

引用

页码：101 / 109

页数：9

共 50 条

[41] LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF QUININE
WANWIMOLRUK, S
CHALCROFT, S
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) : 617 - 620
[42] DEBRISOQUINE OXIDATION PHENOTYPE AND NEUROLEPTIC-INDUCED DYSTONIC REACTIONS
SPINA, E
STURIALE, V
VALVO, S
ANCIONE, M
DIROSA, AE
MEDURI, M
CAPUTI, AP
[J]. ACTA PSYCHIATRICA SCANDINAVICA, 1992, 86 (05) : 364 - 366
[43] METABOLISM OF DEBRISOQUINE AND SUSCEPTIBILITY TO BREAST-CANCER
HUOBER, J
BERTRAM, B
PETRU, E
KAUFMANN, M
SCHMAHL, D
[J]. BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) : 43 - 48
[44] GENETIC SUSCEPTIBILITY TO LUNG-CANCER AS DETERMINED BY LYMPHOCYTIC CHROMOSOME ANALYSIS
DAVE, BJ
HOPWOOD, VL
KING, TM
ZIANG, H
SPITZ, MR
PATHAK, S
[J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1995, 4 (07) : 743 - 749
[45] GENOTYPING OF METABOLIC GENES AS DETERMINANTS OF INDIVIDUAL SUSCEPTIBILITY TO LUNG-CANCER
HIRVONEN, A
HUSGAFVELPURSIAINEN, K
ANTTILA, S
KARJALAINEN, A
VAINIO, H
[J]. MUTATION RESEARCH, 1993, 291 (03): : 242 - 242
[46] DOES GENETIC-VARIABILITY UNDERLIE SUSCEPTIBILITY TO LUNG-CANCER
SCHMIDT, R
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1974, 99 (38) : 1887 - 1888
[47] LUNG-CANCER AND CYP2D6 (THE DEBRISOQUINE POLYMORPHISM) - SOURCES OF HETEROGENEITY IN THE PROPOSED ASSOCIATION
CAPORASO, N
DEBAUN, MR
ROTHMAN, N
[J]. PHARMACOGENETICS, 1995, 5 : S129 - S134
[48] LUNG-CANCER
PARTRIDGE, MR
[J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 1990, 43 (06): : 413 - &
[49] POLYMORPHIC OXIDATION OF DEBRISOQUINE IN BLADDER-CANCER
BENITEZ, J
LADERO, JM
FERNANDEZGUNDIN, MJ
LLERENA, A
COBALEDA, J
MARTINEZ, C
MUNOZ, JJ
VARGAS, E
PRADOS, J
GONZALEZROZAS, F
RODRIGUEZMOLINA, J
USON, AC
[J]. ANNALS OF MEDICINE, 1990, 22 (03) : 157 - 160
[50] LUNG-CANCER
RODESCU, D
[J]. MEDICAL CLINICS OF NORTH AMERICA, 1977, 61 (06) : 1205 - 1218

← 1 2 3 4 5 →